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Abstract
Alternative splicing contributes to proteome diversity. As splicing occurs cotranscriptionally, epigenetic determinants such as DNA methylation likely play a part in regulation of alternative splicing. Previously, we have shown that DNA methylation marks exons and that a loss of DNA methylation alters splicing patterns in a genome-wide manner.
To interrogate the influence of DNA methylation on splicing of individual genes, we developed a method to manipulate DNA methylation in vivo in a site-specific manner using the deactivated endonuclease Cas9 fused to enzymes that methylate or demethylate DNA. We used this system to directly change the DNA methylation pattern of selected exons and introns. We demonstrated that changes in the methylation pattern of alternatively spliced exons, but not constitutively spliced exons or introns, altered inclusion levels. This is the first direct demonstration that DNA methylation of exon-encoding regions is directly involved in regulation of alternative splicing.
Introduction
Alternative splicing (AS) is an evolutionarily conserved mechanism that increases transcriptomic and proteomic diversity and contributes to organismal complexity by enabling the generation of multiple mRNA products from a single gene (Ast 2004; Barbosa-Morais et al. 2006; Will and Luhrmann 2011; Frenkel-Morgenstern et al. 2012; Kornblihtt et al. 2013 ).
About 95% of human multi-exonic genes undergo alternative splicing (Pan et al. 2008; Wang et al. 2008 ). As splicing, or at least the commitment to splicing, occurs co-transcriptionally, epigenetic determinants also play a part in its regulation (Luco et al. 2011; FrenkelMorgenstern et al. 2012; Kwak et al. 2013) . One of these determinants is DNA methylation.
The major site for DNA methylation in mammals is the cytosine at CpG dinucleotide. This epigenetic modification results in 5' methylation of cytosine (5mC) (Hotchkiss 1948; Li and Zhang 2014) . DNA methylation is known to influence gene expression: Hypermethylated
CpG islands in promoters may silence transcription of genes (Bird et al. 1985) , whereas in gene bodies, hypermethylation may cause elevation in gene expression (Ball et al. 2009; Rauch et al. 2009; Laurent et al. 2010) . We recently demonstrated that levels of DNA methylation are higher in genomic regions encoding exons compared to the flanking intron sequences (Gelfman et al. 2013 ). This suggests a functional role of DNA methylation in splicing regulation. Indeed, knockout of all DNA methylation activity has a profound effect on alternative splicing, and manipulation of gene body methylation shows that DNA methylation directly regulates alternative splicing (Song et al. 2017) . DNA methylation regulates alternative splicing by mediating activities of proteins such as CTCF, MeCP2, and HP1 (Shukla et al. 2011; Maunakea et al. 2013; Yearim et al. 2015) . Although these data are suggestive, the importance of exonic DNA methylation for regulation of alternative splicing has not been directly demonstrated.
DNA methyltransferase 3A (DNMT3A) is a part of the DNMT3 protein family, and it is one of the three conserved enzymes responsible for CpG methylation in mammals (Okano et al. 1998 ). Its function is essential for normal development (Li et al. 1992; Okano et al. 1999) .
DNMT3A is responsible for de novo DNA methylation and also error correction (Chedin 2011) . After fertilization all DNA methylation is erased, and, at the blastocyst stage, the DNA methylation pattern is re-established by DNMT3A (Wang et al. 2014) . Structurally, DNMT3A has a catalytic domain, a PWWP domain, and a conserved ATRX-DNMT3-DNMT3L domain (ADD domain) (Chen et al. 2004; Chedin 2011) . Another member of the DNMT3 protein family is DNMT3-like protein (DNMT3L) (Aapola et al. 2000) . DNMT3L
lacks catalytic function, as its catalytic domain is truncated, and it is inactive as a DNA methyltransferase. DNMT3L interacts with DNMT3A (Hata et al. 2002) and significantly stimulates its activity (Chedin et al. 2002; Chen et al. 2005 ).
DNA demethylation is a multi-step process in which 5mC is eventually replaced with a cytosine base (Wu and Zhang 2010) . In the first and main step of demethylation, 5mC is converted to 5hmC by ten-eleven translocation methylcytosine dioxygenase 1 (TET1) (Guo et al. 2011; Xu et al. 2011 ), a member of the TET protein family that mostly functions in the demethylation pathway (Ito et al. 2010; Ito et al. 2011 ). TET1 has a cysteine-rich and DSBH domain (CD), which is the catalytic domain of the enzyme (Tahiliani et al. 2009 ). This domain is sufficient to ensure demethylation of DNA (Maeder et al. 2013 ).
To manipulate DNA methylation in vivo in a site-specific manner we established a method that relies on the clustered regularly interspaced short palindromic repeats (CRISPR) system of bacterial DNA editing. This system has previously been modified to allow epigenetic editing (Jinek et al. 2012; Qi et al. 2013) . Use of the deactivated endonuclease Cas9 (dCas9) allows targeting of a specific DNA sequence without cleavage; in dCas9 both of its endonuclease domains are mutated, but the protein maintains its ability to bind DNA and single guide RNA (sgRNA) (Gilbert et al. 2013) . dCas9 has been used in various biological applications (Mali et al. 2013) . Various techniques to change DNA methylation have been reported. Some are quite difficult to execute and have been limited mainly to promoters and transcription start sites (van der Gun et al. 2010; Maeder et al. 2013; Siddique et al. 2013; Bernstein et al. 2015) , whereas others use dCas9 as a platform to target the DNA (Choudhury et al. 2016; Liu et al. 2016; Morita et al. 2016; Xu et al. 2016; Okada et al. 2017) . None of these studies have examined how DNA methylation of exons and introns affect pre-mRNA splicing and alternative splicing in vivo.
Using dCas9 fused to enzymes that methylate or demethylate DNA, we found that DNA methylation occurs upstream to the sgRNA binding site, whereas the DNA demethylation occurs near the sgRNA binding site. We used this method to manipulate DNA methylation at specific sites within exons and introns and investigated how DNA methylation affects exon inclusion. Our results demonstrated that changes in the methylation pattern of alternatively spliced exons, but not introns or constitutively spliced exons, altered inclusion level. This provides the first direct evidence that DNA methylation of exons is involved in regulation of alternative splicing.
Results
We have previously shown that exons have higher levels of DNA methylation than introns (Gelfman et al. 2013 ), and we and others also showed that DNA methylation plays a regulatory role in alternative splicing of various exons through mechanisms mediated by different proteins (Shukla et al. 2011; Maunakea et al. 2013; Yearim et al. 2015) . Reported experiments do not distinguish whether DNA methylation of exons or introns (or both) is involved in the regulation of these alternative events. In order to examine the importance of DNA methylation of specific gene regions on alternative splicing regulation we developed a method to change DNA methylation in vivo in a site-directed manner. To do so, we utilized the CRISPR technique to target DNA methylation to a specific sequence by fusing the DNMT3A-DNMT3L protein to the deactivated form of CAS9 (dCas9-DNMT3A-3L). We obtained the DNMT3A-DNMT3L from pcDNA3.1-VAZF-3a3lsc(27Linker) plasmid (Siddique et al. 2013 ) (see Methods and Materials). dCas9 can bind to a specific DNA sequence targeted by sgRNA molecules, but due to the lack of endonuclease activity does not cleave the DNA. Co-transfection of dCas9-DNMT3A-3L with sgRNAs is expected to result in methylation of the targeted genomic region with minimal off target methylation (Fig. 1) .
We also designed a reciprocal method to demethylate DNA in vivo site specifically. We fused dCas9 to the core domain of an enzyme necessary for demethylation, TET1. The sequence encoding the catalytic domain (CD domain) of the TET1 protein (Maeder et al. 2013 ) was cloned downstream of dCas9 to enable synthesis of the fusion protein referred to as dCas9-TET1.
To validate the region-specific DNA methylation manipulation system, we used two different cell lines in which the EDI minigene is integrated into the same genomic position and in the same orientation (Yearim et al. 2015 ). The precise genomic location of the minigene integration site is not known (this is a proprietary Invitrogen cell line); however, supplier states that the integration site is intragenic and does not interfere with gene expression of other genes. In one of these Flp-In™-HEK293 cell lines all CpG sites in the EDI minigene are methylated (Met+), whereas in the other cell line the EDI minigene is unmethylated (Met-). We previously showed that the original DNA methylation status is maintained during passages (Yearim et al. 2015) . The EDI minigene is composed of five exons separated by four introns, and exons 3 and 4 are alternatively spliced (exon skipping). EDI is expressed from a fibronectin promoter that drives expression in a DNA methylation-independent manner (Yearim et al. 2015 , Fig. 2A ).
We first examined where the DNA methylation activity of dCas9-DNMT3A-3L occurs relative to the binding site of sgRNA. sgRNAs were designed (Supplemental Table S1 ) to regions up-and downstream and within exon 5 of the EDI minigene (Fig. 2B ). In design of sgRNAs, we used the web tool (http://crispr.mit.edu/). This tool prepares a list of possible sgRNAs in a given DNA sequence and ranks the sgRNAs based on the presence of a PAM sequence, the number of possible off-target hybridization sites in the genome in question, and the genomic location of the site (exonic, intronic, or intergenic). To address this, in each attempt we used different three sgRNAs combination (sgRNA triplet #1, #2 or #3) that target site throughout a region of about 250 bp (Fig. 2B ).
Met-cells were transfected with dCas9-DNMT3A-3L and different sgRNA plasmid combinations and grown for 4 days. Genomic DNA was extracted and treated with bisulfite (BS), which converts cytosine residues to uracil but leaves 5-methylcytosine residues without sgRNAs was 17%, which is considered the background effect of dCas9-DNMT3A-3L.
We also examined the ability of the dCas9-TET1 construct to demethylate DNA in specific sites (Fig. 2D) . Plasmids for expression of dCas9-TET1 and combinations of three sgRNAs were transfected into Met+ cells. After 4 days, CpG methylation in exon 5 was evaluated.
The results indicate that dCas9-TET1 indeed demethylate the DNA. We also found that dCas9-TET1 operates close to sgRNA binding site, as the level of methylation in exon 5 was reduced from about 90% in untreated cells to about 7% in cells that expressed dCas9-TET1
and an sgRNA combination with complementarity to exon 5 (Fig. 2B , green arrows and Fig.   2D , green column). Thus, with these two fusion proteins and the right combination of sgRNAs, it is possible to manipulate DNA methylation in a desired region of the genome in live cells. To assess possible off target activity of the sgRNAs, we examined the methylation status for one or two top off-target hybridization sites for each positive sgRNAs co-
transfected with dCas9-DNMT3A-3L or dCas9-TET1, used in figure 2. For most of the sgRNAs, we did not observe any significant changes in the DNA methylation between the different samples. This indicates there was not an off-target binding or activity of dCas9 fused protein with or without any of the sgRNAs ( Supplementary Fig. 1 ).
In order to further investigate the functionality of the fusion protein dCas9-TET1, we examined a larger region of the EDI minigene for effects on methylation. We overexpressed dCas9-TET1 with the sgRNA combination targeting exon 5 (Fig. 2D , green arrows). DNA methylation was evaluated in six regions spanning about 1 kb upstream of exon 5 (Fig. 3A regions F, G), and downstream of exon 5 (Fig. 3A regions B, C, D) and within exon 5 (Fig.   3A , region A). After BS treatment, only these regions were amplified with specific primers and deep sequenced to acquire reads specific for the EDI locus. The reads were mapped to the EDI minigene to identify sites of DNA methylation. The CpG methylation levels of the control sample (dCas9-TET1 without sgRNA) in the regions in the EDI minigene (F, G, A, B) were high as expected for these Met+ cells (Fig. 3B) . In cells in which both dCas9-TET1
and sgRNA were expressed, methylation in region A was lower by about 50% compared to the control sample; methylation was not altered in regions B, F, or G (Fig. 3B ). Regions C and D had low levels of CpG methylation in both control and test samples (Fig. 3B ). We assume it is related to the fact that they are located within the pFRT integration plasmid and the lacZ promoter which is part of it, and thus are not uniformly DNA methylated as the EDI minigene. Overall, these results indicate that the range of demethylation by dCas9-TET1 fusion protein is limited to a few hundred base pairs surrounding the sgRNA target zone.
DNA methylation of exons affects alternative splicing
Next, we manipulated DNA methylation within the EDI minigene and examined how this influenced alternative splicing. sgRNAs were designed to the alternative exons in the EDI minigene, exon 3 and exon 4, and intronic regions located 250 bp downstream of these exons (Fig. 4A) . We overexpressed dCas9-DNMT3A-3L or dCas9-TET1 with the various sgRNA combinations in Met-or Met+ cell lines, respectively. Each region was targeted with three sgRNAs to target the fusion proteins to an approximately 200-bp region. After four days, total RNA was extracted, and the EDI splicing pattern (the inclusion level of both alternative exons 3 & 4) was examined by reverse transcription followed by qualitative PCR (RT-qPCR)
analysis.
dCas9-DNMT3A-3L and dCas9-TET1 exerted different effects on the splicing of the EDI pre-mRNA. In Met-cells, dCas9-DNMT3A-3L activity caused an elevation in the inclusion level of the alternatively spliced exons when the sgRNAs targeted the methylation activity to the exons themselves (Fig. 4B ). Although these alterations in the inclusion levels were not statistically significant, the direction in the shift of the splicing pattern is visible. In contrast, in Met+ cells, when sgRNAs targeted dCas9-TET1 to exons or to introns, the inclusion levels decreased significantly (Fig. 4C ). This indicates that DNA methylation has a positive effect on the alternative splicing regulation of the EDI minigene, since the lack of DNA methylation hinders the recognition of exon 3 & 4 as exons and their inclusion in the mature mRNA. This effect on the EDI inclusion levels was seen only when the alternative exons were targeted, as the inclusion level did not change when a constitutive exon (exon 5, for DNA methylation levels see Fig. 2 ) or the middle of an intron were targeted ( Supplementary Fig. 2 ).
DNA methylation levels for each of the two alternatively spliced exons were examined in the Met+ cell line after overexpressing dCas9-TET1 with or without the sgRNA triplets. When dCas9-TET1 with sgRNAs targeting alternatively spliced exons or introns, there was a decrease in the methylation levels compared to cells in which only dCas9-TET1 was expressed (Fig. 4D ). Although the change in the methylation was not large (between 15 and 30%), it was enough to cause a shift in the inclusion level of the alternative exons. Moreover, no significant change in the transcription level of the EDI minigene was observed in the Met+ cell line after dCas9-TET1 OE with or without sgRNAs. In the Met-cell line, a slight downregulation was observed when the dCas9-DNMT3A-3L was targeted downstream to one of the alternative exons. However, this downregulation did not correspond to the decrease in the inclusion level of the alternative exons of the EDI minigene ( Supplementary   Fig. 3 ).
To further examine the importance of DNA methylation of exon on the regulation of exon selection and splicing, we used this technique to demethylate an exon in an endogenous gene and examined its splicing pattern in HCT 116 cells, a colorectal carcinoma cell line. We chose exon 5 of the DHODH gene as it inclusion levels were downregulated in DNMT1 and DNMT3B double knockout HCT 116 cells compared to the wild-type HCT 116 cells (Maunakea et al. 2013) . Various sgRNAs were designed to target either DHODH exon 5 or its flanking introns. Intron 4 and intron 5 targeted sgRNAs were designed to hybridize approximately at the middle of the introns and away from any splice sites (Fig. 5A) . These sgRNAs were then cloned into separate expression vectors. The sgRNAs (two per region)
were co-transfected with the dCas9-TET1 expression plasmid into HCT 116 cells. As a control, cells were transfected with only the dCas9-TET1 plasmid. Following an incubation period of 4 days, cells were harvested and total RNA was extracted. Initially, to examine the splicing pattern of the exon, reverse transcription PCR (RT-PCR) was performed using primers designed to evaluate splicing of exon 5. In the presence of the DHODH exon 5 targeted sgRNAs, the splicing pattern shifts towards the skipped isoform as compared to the control sample (Fig. 5B) . To further this, RT-qPCR analysis indicated a significant decrease of about 20% in the inclusion level of DHODH exon 5 when exon 5 was targeted for demethylation, whereas no significant change in splicing was observed when sgRNAs targeting the surrounding introns were used (Fig. 5C ). The DNA methylation levels of DHODH exon 5 were also evaluated by extracting genomic DNA and performing BS conversion and sequencing with primers specific for the exon 5 region. The DHODH exon 5
is fully methylated when dCas9-TET1 is not targeted to exon 5 (Fig. 5D , left). The DNA methylation levels decreased by 15% when exon 5 targeting sgRNAs were used (Fig. 5D , right). This decrease in methylation levels is similar to that observed when the EDI minigene alternative exons were targeted for demethylation (Fig. 4D ). This further indicates that DNA methylation of exon is more important for splicing regulation than introns.
Discussion
Here we demonstrate a method, based on the CRISPR technology (Mali et al. 2013; Choudhury et al. 2016; Liu et al. 2016; Morita et al. 2016; Okada et al. 2017 interesting, but not surprising, that dCas9-DNMT3A-3L and dCas9-TET1's direction of function is not the same; one functions upstream to its DNA binding site, whereas the other functions on a range of a few hundreds of bases at the DNA binding site itself, respectively.
We attribute this difference to the location of the active site in the fused protein. Perhaps In both examples we targeted for demethylation, sgRNAs were designed to hybridize to internal exons and thus affect their alternative splicing. There may be specific CpG methylation positions that are more important than the others, but at the resolution of the
current experiments, this cannot be determined. Mechanistically, DNA methylation may influence alternative splicing by altering the level of tri-methylation of histone 3 at lysine 9 (H3K9me3). The H3K9me3 recruits HP1 proteins, which bind several alternative splicing regulatory proteins, to generate a high concentration of these regulatory proteins on alternative exons at the chromatin level (Yearim et al. 2015) . We assume that during transcription, the splicing factors move from the chromatin onto the alternative exons at the RNA level and thus regulate their splicing in a site-specific manner.
Processes other than splicing are also likely to be influenced by DNA methylation. For example, it has been shown by others that methylation of promoters can cause gene silencing (Choudhury et al. 2016; Liu et al. 2016; Morita et al. 2016; Xu et al. 2016; Okada et al. 2017 ). The method we describe here has potential to be a powerful tool to investigate many different regulatory processes. This method can be used to examine whether epigenetic features such as GC content, chromatin modifications, or genomic location (inter or intragenic) impact the activity of TET1 or DNMT3A enzymes and will promote our understanding of how DNA methylation regulates various cellular activities.
Methods and Materials

dCas9-DNMT3A-3L cloning
The cloning of the pcDNA-dCas9-DNMT3A-DNMT3L-T2A-Puromycin (dCas9-3A3L) was done using Gibson assembly as described in Gibson bp. The primers were synthesized at IDT, and sequences are as follows: 
dCas9-TET1 cloning
The cloning of the pcDNA-dCas9-TET1_CD-T2A-Puromycin (dCas9-TET1) was done using Gibson assembly essentially as described above using the following primers:
T2A-Puromycin insert
Puro_TET1 GIB FWD: 5'-tgctctcacacacgttgcggggccctataaccattgggtctctagagggcccttcgaaca-3' GIB pur_dCAS Rev: 5'-caactagaaggcacagtcgaggctgatcagcggtttaaactcaggcaccgggcttgc -3'
A stop codon (represented by capital G in TET1CD_C7 GIB FWD primer) was disrupted, and the open reading frame was maintained by adding two nucleotides as spacer between inserts (represented by AA at TET1CD_C7 GIB FWD primer). The TET1_CD insert was amplified from pJFA344C7 (Maeder et al. 2013) . were seeded into 12-well plates (140,000 cells in each well). For dCas9-DNMT3A-3L overexpression, cells were co-transfected 24 h after plating with either with 400 ng dCas9-3A3L plasmid and 177 ng of each of three different sgRNA expression plasmids or 931 ng dCas9-3A3L plasmid or were untreated. For dCas9-TET1 overexpression, at 24 h after plating, cells were co-transfected with 400 ng dCas9-TET1 plasmid and 166 ng of each of three sgRNA expression plasmids or 898 ng dCas9-TET1 plasmid or were untreated.
Transfection was done using TransIT®-LT1 (Mirus Bio), according to the manufacturer's recommended protocol. A similar protocol was used in experiments with the HCT 116 cells with the following changes: approximately 300,000 cells were seeded in 6-well plate, and after 24 h cells were co-transfected with 1 µg dCas9-TET1 plasmid and 415 ng of each of two sgRNA expression plasmids or 1.83 µg dCas9-TET1 plasmid or were untreated.
Following transfection, cells were incubated for 4 days and then genomic DNA was extracted using High Pure PCR Template preparation kit (Roche) or using the following protocol: Cells from each well were pelleted by centrifugation and washed with PBS. Pellets were resuspended in DNA Lysis Buffer (50 mM Tris-HCl, 60 mM NaCl, 0.65% SDS, 0.8 mg/ml Proteinase K (NEB)) and incubated at 37 °C overnight or at 55 °C for 3 h. Samples were treated with RNase A. DNA was extracted using Phase Lock Gel tubes (5Prime) and phenol:chloroform:isoamyl alcohol (25:24:1) saturated with 100 mM Tris, pH 8.0 (Sigma) according to the protocol provided by 5Prime. One-tenth volume of 3 M NaOAc and 2.5 volumes of cold ethanol were added. Samples were incubated either in -80 °C for 1 h or at -20 °C overnight and then centrifuged at 10000 rpm for 15 min at 4 °C. Then samples were washed with cold 70% ethanol, centrifuged for 5 min at 10000 rpm at 4 °C, and supernatant removed. Pellets were air dried for 15 min and re-suspended in nuclease-free water.
Bisulfite DNA methylation analysis
Genomic DNA samples (500 ng) were bisulfate converted using EZ DNA Methylation kit Supplemental Table S1 . Table S1 .
Cell culture
Flp-In-HEK293 cells stably transformed with the methylated or unmethylated EDI minigene were cultured in complete DMEM medium with high glucose (Sigma), 10% fetal bovine serum (Sigma), 2 mg/ml L-alanyl-L-glutamine (Biological Industries Israel), 100 U/ml penicillin, 0.1 mg/ml streptomycin (Biological Industries Israel) supplemented with 100 µg/ml hygromycin B (InvivoGen). HCT 116 human colon carcinoma cells were cultured in complete RPMI medium with high glucose (Sigma), 10% fetal bovine serum (Sigma), 2 mg/ml L-alanyl-L-glutamine (Biological Industries Israel), 100 U/ml penicillin, and 0.1 mg/ml streptomycin (Biological Industries Israel). All cells were grown at 37 °C in a humidified atmosphere with 5% CO 2 .
Deep sequencing and bioinformatics analysis of DNA methylation
After genomic DNA extraction and bisulfite conversion, regions of interest were amplified using primers designed for bisulfite DNA sequencing that have a 3' tail of eight random nucleotide (N). This tail was added in order to remove redundant reads created by PCR bias.
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